ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

アビラテロン

Abiraterone

HCID 132971
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
154229-19-3
標準SMILES
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
InChIKey
GZOSMCIZMLWJML-VJLLXTKPSA-N
分子式
C24H31NO
平均分子量
349.5 g/mol
単同位体質量
349.24056461

概要

Abiraterone is a 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer. It has a role as an antineoplastic agent and an EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor. It is a 3beta-hydroxy-Delta(5)-steroid, a member of pyridines and a 3beta-sterol. It derives from a hydride of an androstane.

名称と識別子

優先名称
Abiraterone
IUPAC
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
現地名
アビラテロン
英語名
Abiraterone
分子式
C24H31NO
分子量
349.52

名称と別名

Abiraterone154229-19-3CB 7598CB-759817-(3-Pyridyl)androsta-5,16-dien-3beta-olAbirateronaabirateronumCB759817-(pyridin-3-yl)androsta-5,16-dien-3beta-ol(3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-olAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3beta)-(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
名称をさらに表示
アビラテロン17-(3-ピリジル)アンドロスタ-5,16-ジエン-3β-オール3β-ヒドロキシ-17-(ピリジン-3-イル)アンドロスタ-5,16-ジエン3β-ヒドロキシ-17-(3-ピリジル)-アンドロスタ-5,16-ジエン17-(3-ピリジニル)アンドロスタ-5,16-ジエン-3β-オール(3aS,3bR,7S,9aR,9bS,11aS)-9a,11a-ジメチル-1-(ピリジン-3-イル)-3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-シクロペンタ[a]フェナントレン-7-オール収差(3S,8R,9S,10R,13S,14S)-10,13-diMethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-olAberration7-Keto Abiraterone Acetate(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-olCS-211AbironAbytron
G819A456D0NSC-741232CHEBI:68642DTXSID80879993(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta(a)phenanthren-3-olRefChem:57133L02BX03DTXCID501021626

物性

構造計算による物性

XLogP
4.6
極性表面積
33.1 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
1
重原子数
26
形式電荷
0
複雑度
636

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Metabolite of Abiraterone acetate

Pharmaceuticals -> Listed in ZINC15

Human DrugsHormones and antihormones
Endocrine DisruptorsPotential endocrine disrupting compound

物理化学的性質

融点
227 · 227-228 °C(Solv: toluene (108-88-3))
沸点
500.2 · 500.2±50.0 °C(Predicted)
比重(密度)
1.14 · 1.14±0.1 g/cm3(Predicted)
貯蔵温度
2 · 2-8°C
溶解性
クロロホルム(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
14.71 · 14.71±0.70(Predicted)
色
白色~淡黄色
InChIKey
GZOSMCIZMLWJML-DROLTIPTNA-N
SMILES
C[C@]12CC[C@]3([H])[C@]4(CC[C@H](O)CC4=CC[C@@]3([H])[C@]1([H])CC=C2C1=CN=CC=C1)C |&1:1,4,6,9,15,17,r|
CAS データベース
154229 · 154229-19-3

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H360 (57.1%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 7 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationREACH registered substance: (1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵] heptadeca-7,13-dien-5-ol (EC: 810-941-6)
Hazard Classes and CategoriesRepr. 1B (57.1%)

毒性情報

Hepatotoxicity · 1 件

Serum aminotransferase elevations occur in up to 13% of patients treated with abiraterone compared with 1% to 8% receiving placebo or a comparator drug, but the abnormalities are generally mild, transient and not associated with symptoms or jaundice. ALT elevations above 5 times the upper limit of normal (ULN) occur in 6% of abiraterone treated vs

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Abiraterone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

ATC Code · 4 件

L02BX03

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

L02BX03

Protein BindingAbiraterone is highly bound (>99%) to the human plasma proteins, albumin and alpha-1 acid glycoprotein.
Pharmacodynamics · 1 件

_In vivo_, abiraterone acetate is rapidly hydrolyzed to abiraterone, which mediates its pharmacological actions. Abiraterone decreases serum testosterone and other androgens. A change in serum prostate-specific antigen (PSA) levels may be observed.

Mechanism of Action · 1 件

17α-hydroxylase/C17,20-lyase (CYP17) is a key enzyme in androgen biosynthesis. It is primarily expressed in testicular, adrenal, and prostatic tumours. CYP17 catalyzes the 17α-hydroxylation of pregnenolone and progesterone to their 17α-hydroxy derivative, followed by subsequent cleavage of the C 20,21-acetyl group to yield dehydroepiandrosterone (DHEA) and androstenedione. DHEA and androstenedione are precursors of testosterone. Aberrant androgen levels and unregulated androgen receptor signalling have been implicated in the development and progression of various prostate cancers. Androgen-sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumour. Abiraterone inhibits CYP17 to block androgen production. Inhibition of CYP17 can also result in increased mineralocorticoid production by the adrenals.

Biological Half-LifeIn patients with mCRPC, the mean (± SD) terminal half-life of abiraterone in plasma is 12 (± 5) hours.
Metabolism/Metabolites · 2 件

The conversion of abiraterone acetate to abiraterone, the active metabolite, is likely to be mediated by esterases, although specific esterases have not been identified. In human plasma, the two main circulating metabolites are abiraterone sulfate, which is formed by CYP3A4 and SULT2A1, and N-oxide abiraterone sulfate, which is formed by SULT2A1. These metabolites each account for about 43% of abiraterone exposure and are pharmacologically inactive.

関連反応

14 件
反応記録を作成
HRID 53180 の反応式
HRID 53180生成物として
HRID 53189 の反応式
HRID 53189生成物として
HRID 53190 の反応式
HRID 53190反応物として
HRID 348776 の反応式
HRID 348776生成物として
HRID 525309 の反応式
HRID 525309反応物として
HRID 531211 の反応式
HRID 531211反応物として
HRID 531212 の反応式
HRID 531212反応物として
HRID 531213 の反応式
HRID 531213反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
154229-19-3
PubChem CID
132971
DTXSID
DTXSID80879993
ChEMBL
CHEMBL254328
ChEBI
CHEBI:68642
UNII
G819A456D0
EC Number
810-941-6
Nikkaji
J617.457D

化学的性質

化学的特性White Solid

Abiraterone has known human metabolites that include abiraterone sulfate.

FDA Pharmacological Classification · 6 件

G819A456D0

ABIRATERONE

Mechanisms of Action [MoA] - Cytochrome P450 17A1 Inhibitors

Established Pharmacologic Class [EPC] - Cytochrome P450 17A1 Inhibitor

Mechanisms of Action [MoA] - Cytochrome P450 2D6 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C8 Inhibitors

Absorption, Distribution and Excretion · 3 件

Geometric mean (± SD) Cmax was 73 (± 44) ng/mL and AUC0-∞ was 373 (± 249) ng x hr/mL following a single dose of 500 mg abiraterone acetate in overnight-fasted healthy subjects. Dose proportionality was observed in single doses of abiraterone acetate ranging from 125 mg to 625 mg. A group of patients with mCRPC received a daily dose of 1,000 mg: at steady-state, the mean (± SD) Cmax was 226 (± 178) ng/mL and AUC was 993 (± 639) ng x hr/mL. Following oral administration of abiraterone acetate to patients with metastatic castration-resistant prostate cancer, the median Tmax was two hours. _In vivo_, abiraterone acetate is converted to abiraterone. In clinical studies of other abiraterone acetate formulations, abiraterone acetate plasma concentrations were below detectable levels (< 0.2 ng/mL) in > 99% of the analyzed samples. Systemic exposure to abiraterone is increased when abiraterone acetate is administered with food. Abiraterone Cmax was approximately 6.5-fold higher, and AUC0-∞ was 4.4-fold higher when a single dose of abiraterone acetate 500 mg was administered with a high-fat meal (56-60% fat, 900-1,000 calories) compared to overnight fasting in healthy subjects. Given the normal variation in the content and composition of meals, taking abiraterone with meals has the potential to result in increased and highly variable exposures.

Following oral administration of <sup>14</sup>C-abiraterone acetate, approximately 88% of the radioactive dose is recovered in feces: the major compounds present in feces are unchanged abiraterone acetate and abiraterone, accounting for approximately 55% and 22% of the administered dose, respectively. Approximately 5% of the dose is recovered in urine.

The mean (± SD) apparent steady-state volume of distribution is 19,669 (± 13,358) L.

応用分野 · 3 件

解説レンズなどによる光学結像のさいの理想像からの幾何光学的なずれ.ふつう,光軸のまわりに回転対称な系について考え,単色光に対する光線収差と,白色光などの場合の波長の分散に基づく色収差とを問題とする.

来歴Abiraterone (brand name: Zytiga) is an anti-cancer drug developed by Centocor Ortho Biotech Inc. It was first approved by the FDA on 28 April 2011 for the treatment of advanced prostate cancer. In December 2012, the FDA expanded Zytiga's approved use to include treatment of men with advanced (metastatic) castration-resistant prostate cancer prior to chemotherapy. By February 2018, the FDA further approved Zytiga (abiraterone acetate) in combination with prednisone for the treatment of early metastatic prostate cancer.

使用Abiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr ostate cancer.

上流・下流製品情報

上流原料

炭酸ナトリウムビス(トリフェニルホスフィン)パラジウム(II)ジクロリド水酸化ナトリウム塩酸ジエチル(3-ピリジル)ボラン

下流製品

酢酸アビラテロン

補足説明

定義ChEBI: A 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cance .